Valeant Pharmaceuticals International (VRX) Sets New 1-Year High at $25.00

Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)’s share price hit a new 52-week high on Friday . The stock traded as high as C$25.00 and last traded at C$22.68, with a volume of 2166709 shares changing hands. The stock had previously closed at C$21.52.

Several brokerages have commented on VRX. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a C$23.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. TD Securities raised shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price for the company in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Valeant Pharmaceuticals International presently has an average rating of “Hold” and an average target price of C$22.50.

In other news, Director Schutter Richard Urbain De bought 10,000 shares of the stock in a transaction on Friday, November 17th. The stock was purchased at an average price of C$14.33 per share, with a total value of C$143,300.00.

ILLEGAL ACTIVITY NOTICE: This story was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply